Forty-one patients who had undergone bone marrow transplantation were examined. Nineteen (63%) of the 30 who had received fractionated total body irradiation (TBI) had cataracts in comparison with only 1 (9%) of the 11 non-irradiated patients. No significant differences in steroid therapy were demonstrated between these groups of patients. Dry eyes were observed in eight irradiated patients, seven of whom had preceding graft-versushost disease. Superficial punctate staining of the bulbar conjunctiva was observed in 25 (83%) of the irradiated group and, in milder form, in five (45%) of the non-irradiated group, Our data suggest that the incidence of cataract following fractionated TBI is influenced not only by the total dose of radiation but also by its rate of administration (defined by midline tissue dose rate and fractionation schedule). In addition dry eyes and conjunctival staining may be exacerbated by TBI, though other aspects ofconditioning may also be implicated.
Bone marrow transplantation (BMT) is an established treatment for haematological malignancy.' Patients undergoing transplantation receive conditioning treatment which may include total body irradiation (TBI) to eradicate both tumour and recipient marrow cells. The eyes are not normally shielded during TBI because they are a potential site of leukaemia relapse. After the conditioning treatment patients receive either autologous marrow harvested during apparent remission from disease or allogeneic marrow from a tissue matched donor.
Graft-versus-host disease (GVHD) is a major complication of allogeneic BMT.2A It results from a reaction of immunocompetent donor marrow cells with recipient (host) tissues, and affects principally the skin, gastrointestinal tract, and liver. It may require treatment with large doses of systemic steroids. Ocular complications are common. 5 '0 Transplant patients are consequently at considerable risk of developing cataracts as a result of their exposure both to TBI' lo and to systemic steroids." The relative risk to these patients of developing cataract is reported to be significantly reduced by either fractionating the TBI or omitting it completely. ' The purpose ofthis study was to determine the incidence of ocular complications in a group of long term survivors of BMT who had received chemotherapeutic tumour ablation either alone or in combination with fractionated TBI. (Table 2) , and tended to be more severe in patients with GVHD.
There were insufficient data to allow statistical comparisons of steroid doses and post-transplant review times between the three groups. Mean steroid doses for the three groups were broadly similar, as were mean post-transplant review times for autologous and allogeneic grafts receiving TBI (Table 3) . However, review times for group 3 were somewhat shorter than for the other groups.
Overall, the incidence of cataracts was 63% (19 of 30) of those patients who received TBI prior to transplantation and 9% (1 of 11) of the nonirradiated patients. There were no significant difference in steroid therapy between those who developed cataracts (including the non-irradiated cataract patient) and those who did not (Table 4) . However, post-transplant review times were significantly greater in the former group than in the latter (Table 4) .
Discussion
The association between cataract formation and exposure to ionising radiation was first recognised in the last century.'4 The relationship depends not only on total dose used, but on the rate of exposure, as illustrated by Merriam and Focht, '5 who estimated the minimum dose of radiation required to produce a cataract varied from 2 Gy if given as a single dose to 5 5 Gy if given over longer than three months. However, cataract formation was not observed in some patients receiving as much as 11 Gy. Similarly, dramatic differences in the incidence and severity of cataract were observed in BMT patients receiving TBI at different rates of exposure.8 In a large comparative study in Seattle, the reported incidence of cataract was 80% in those receiving single shot TBI Three additional factors were said by Deeg and colleagues' group8 to contribute to the development of cataract in these patients: a history of acute or chronic GVHD, steroid usage after day 100 ('chronic usage'), and an initial diagnosis of acute lymphoblastic leukaemia. They could not separate the importance of GVHD from the use of steroids in these patients because the two were so highly associated. They suggested that the high incidence in patients with acute lymphoblastic leukaemia may be related to the high pre-transplant doses ofsteroids used, a finding confirmed in a subsequent study.9 Among our patients neither steroid therapy nor the frequency of acute lymphoblastic leukaemia appeared to be significantly different between those who developed cataracts and those who didnot (though our patient group is small). There was a strong association between the presence of cataract and a history of GVHD, apparently without the excessive use ofsteroids in this group (8 of the 12 patients had received less than the mean steroid dose for the 'cataract present' group as a whole).
In theory the higher incidence of cataract observed in our study could be explained by differences in steroid administration. Comparisons of steroid therapy between studies are difficult to make, as their measurement is inevitably crude, depending not only on total dose but on duration, type, and relative potency of the particular steroid used in each case. We do not believe that the use of steroids in our group was unusually excessive or at variance with accepted practice, rendering this explanation unlikely.
There were differences both in midline tissue dose rate and fractionation schedule of the TBI administration between our study and the Seattle study8 which may be significant. All our patients received a midline tissue dose of 0-25 Gy/min in comparison to just 0-04-0-08 Gy/min for theirs. Secondly, our patients were subjected to TBI fractionated over just 1 5-3 In our study one case of dry eyes was observed in an allogeneic recipient without a history of GVHD. It is known that higher doses of orbital irradiation, in the region of 32-45 Gy, are usually well tolerated but may be associated with dry eyes.l6 One study reports three cases of dry eyes in patients receiving only 12 Gy.7 Superficial punctate epitheliopathy was an almost universal finding in patients who had undergone TBI and was present, but in less severe form, in nonirradiated patients. It would seem reasonable to ascribe these abnormalities, at least in part, to a toxic effect of TBI on the eye, though its presence in non-irradiated patients suggests that other aspects of the pre-transplant conditioning may also be implicated.
In conclusion, our data suggest that the relationship between irradiation and ocular toxicity is complex, depending not only on total dose but also its rate of administration (that is, midline tissue dose and/or fractionation schedule). Ocular complications may seem trivial in comparison with the serious nature of the systemic disease under treatment, but can assume greater significance in those 55-90% of patients who become long-term survivors of BMT. Careful scheduling of TBI and the sparing use of steroids are of the utmost importance in minimising these complications.
